Meta-Analysis of IBS-C Drug Trials: Efficacy and Safety of Linaclotide and Plecanatide

5,718 patients with irritable bowel syndrome with constipation (IBS-C) from 9 randomized controlled trials are analyzed in this systematic review and meta-analysis. The dataset, authored by Zihao Zhou and last updated in April 2026, compares the efficacy and safety of guanylyl cyclase C agonists (linaclotide and plecanatide) against placebo.

Use Cases

• Compare relative risk for FDA composite endpoint achievement between drug dosages and placebo.
• Analyze the trade-off between symptom improvement and adverse events like diarrhea.
• Validate statistical findings from the meta-analysis using the underlying trial data.
• Benchmark new IBS-C treatments against established efficacy and safety profiles.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes specific relative risk (RR) and confidence interval results for primary and safety outcomes.
• Registered with PROSPERO (CRD420251168079), indicating a predefined protocol.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 30.1 KB file size suggests the dataset is a summary table, not the full underlying patient-level data.

Provenance

Source

Systematic review and meta-analysis authored by Zihao Zhou, published on figshare.

Collection Method

Data extracted from randomized controlled trials identified via systematic search of PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov.

Time Range

Search timeframe spans from database establishment to 7 September 2025.

Freshness

Last updated 2026-04-10 05:58:44; freshness should be verified.

Geography

null